National Engineering Research Center of Seafood, School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, China.
College of Food Science and Technology, Northwest University, Xi'an 710069, China.
Food Funct. 2022 Jun 6;13(11):6259-6270. doi: 10.1039/d2fo00480a.
Previous studies have indicated that fucoidan could resist high-fat-diet (HFD)-induced obesity by modulating the composition of gut microbiota. However, the outcome of dietary intervention may differ between individuals due to large inter-individual variability in gut microbiota. Thus, the present study aimed to investigate the possible discrepancy of the anti-obesity effects of fucoidan supplementation in HFD-fed mice models with different gut microbiota communities. In the present study, the anti-obesity effects of fucoidan isolated from (Fuc) on normal mice and microbiota-altered mice treated with penicillin or metronidazole were compared and investigated. The 16S rRNA sequencing revealed the differences of gut microbiota among penicillin-treated, metronidazole-treated and normal groups, and mice treated with penicillin were characterized by greater relative abundance of the phylum Bacteroidetes and the families Muribaculaceae and Bacteroidaceae. Furthermore, Fuc ameliorated HFD-induced body weight gain, fat accumulation, serum lipid profiles, insulin resistance, hepatic steatosis and adipocyte hypertrophy in penicillin-treated and untreated mice, while no effects were observed in metronidazole-treated mice. Overall, mice with different initial gut microbiota responded differently to Fuc supplementation on a high-fat diet, and metronidazole-sensitive gut bacteria negatively correlated with obesity symptoms and were required for the anti-obesity effects of Fuc. Moreover, the anti-obesity effects were not dependent on the utilization of Fuc by gut microbiota to produce SCFAs. These findings indicate that evaluation of the gut microbiota structure before dietary interventions is helpful for enhancing the beneficial outcomes of dietary fiber supplementation and provide a rationale for the further application of dietary fucoidan in a personalized way.
先前的研究表明，褐藻糖胶可以通过调节肠道微生物群落的组成来抵抗高脂肪饮食（HFD）诱导的肥胖。然而，由于肠道微生物群落存在个体间的巨大差异，饮食干预的结果可能因人而异。因此，本研究旨在研究不同肠道微生物群落的 HFD 喂养小鼠模型中褐藻糖胶补充的抗肥胖作用的可能差异。在本研究中，比较并研究了从 （Fuc）中分离得到的褐藻糖胶对正常小鼠和用青霉素或甲硝唑处理的菌群改变小鼠的抗肥胖作用。16S rRNA 测序揭示了青霉素处理组、甲硝唑处理组和正常组之间肠道微生物群落的差异，并且用青霉素处理的小鼠的特征是厚壁菌门和 Muribaculaceae 科和 Bacteroidaceae 科的相对丰度更大。此外，Fuc 改善了青霉素处理和未处理小鼠的 HFD 诱导的体重增加、脂肪积累、血清脂质谱、胰岛素抵抗、肝脂肪变性和脂肪细胞肥大，而在甲硝唑处理的小鼠中没有观察到这些作用。总的来说，具有不同初始肠道微生物群的小鼠对高脂肪饮食中褐藻糖胶补充的反应不同，并且对甲硝唑敏感的肠道细菌与肥胖症状呈负相关，并且是 Fuc 抗肥胖作用所必需的。此外，抗肥胖作用不依赖于肠道微生物利用 Fuc 产生 SCFAs。这些发现表明，在饮食干预之前评估肠道微生物群落结构有助于增强膳食纤维补充的有益结果，并为进一步以个性化方式应用饮食褐藻糖胶提供了依据。
